Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Novartis
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
A randomized open-label study of 400 mg versus 800 mg of Gleevec/Glivec (imatinib mesylate) in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints
To establish whether 800 mg Gleevec/Glivec (as 400 mg bid) improves efficacy in newly diagnosed, previously untreated CML-CP patients as compared to 400 mg by the evaluation of the rate of molecular r...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Novartis Pharmaceuticals Corporation
Update Il y a 5 ans
A 2-year randomized, multicenter, double-blind, placebocontrolled study to determine the efficacy and safety of intravenous zoledronic acid 5 mg administered either annually at randomization and 12 months, or administered at randomization only in the prevention of bone loss in postmenopausal women with osteopenia
- To demonstrate that zoledronic acid 5 mg i.v. given annually at randomization and Month 12 is superior to placebo in percent change of BMD at the lumbar spine at Month 24 relative to baseline in Str...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
A randomized, double-blind, placebo-controlled, multi-center, two-period crossover study to investigate the bronchodilatory effect of 50µg NVA237 inhaled once daily in patients with Chronic Obstructive Pulmonary Disease (COPD)
Investigate the bronchodilatory efficacy of 50µg NVA237 over 24 hours following 14 days treatment when compared to placebo.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
Study of efficacy and safety of VAY736 in patients with relapsing-remitting multiple sclerosis
To determine if a monoclonal antibody VAY736 can reduce disease activity in relapsing-remitting multiple sclerosis (RRMS) as compared to placebo.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma AG
Update Il y a 5 ans
Efficacy of secukinumab compared to adalimumab in patients with psoriatic arthritis
To demonstrate that the efficacy of secukinumab monotherapy (300 mg s.c.) at Week 52 is superior to adalimumab monotherapy (40 mg s.c.) based on the proportion of subjects achieving an American Colleg...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Novartis Pharma
Update Il y a 5 ans
CMEK162X2111: Essai de phase 1b/2 évaluant l’efficacité de l’association de MEK162 et du ganitumab, chez des patients ayant une tumeur solide avancée, avec une mutation de KRAS ou de BRAF. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est de déterminer la dose la mieux adaptée de l’association de MEK162 et de ganitumab à administrer et d’évaluer l’efficacité de cette association, chez des patients ayant une ...
Country
France
organs
Tumeurs solides
,
Côlon ou Rectum (colorectal)
,
Pancréas
,
Mélanomes cutanés
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
Phase I study of LDK378 in pediatric malignancies with a genetic alteration in ALK
Estimate the MTD and/or RDE of LDK378 as a single agent when administered orally to pediatric patients with ALK-activated tumors in the fasted and fed state
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 5 ans
Exploratory evaluation of surrogate markers of cardiovascular risk in patients with active chronic plaque-type psoriasis
To evaluate flow mediated dilation (FMD) by Doppler ultrasound at week 12 in subjects in treatment arm A (300 mg Secukinumab) compared to the pooled group of patients in treatment arms C and D (placeb...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma S.A.S
Update Il y a 5 ans
Efficacy of Rasilez® (Aliskiren) compared to ramipril in the treatment of moderate systolic hypertensive patients
Comparer l'efficacité d'aliskiren 150/300 mg à celle de ramipril 5/10 mg sur la réduction de la PASma à l’état final (V4 soit après 8 semaines de traitement en double-aveugle) par rapport à l'état bas...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 5 ans
Pharmacokinetics, pharmacodynamics and safety of DEB025/alisporivir in combination with ribavirin therapy in chronic hepatitis C genotype 2 and 3 patients who have previously failed interferon therapy or are intolerant or unable to take interferon
To evaluate pharmacodynamics, pharmacokinetic between 2 treatment groups receiving different doses of DEB025 in combination with RBV
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next